1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,100 | 26,200 | 11:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | BASTIDE: Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in home healthcare services, up 10.7% / Homecare business up 4.7%, driven by the healthcare institutions business (up 8.5%) | 311 | Actusnews Wire | Caissargues, November 13, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2025-2026, ending September 30, 2025.
In... ► Artikel lesen | |
| 28.10. | BASTIDE: 2025-2026 financial calendar | 833 | Actusnews Wire | Caissargues, October 28, 2025
Events
Dates*
2025-2026 Q1 Revenue
Thursday November 13, 2025
2025-2026 H1 Revenue
Thursday February 12, 2026
2025-2026 H1 Results
Wednesday... ► Artikel lesen | |
| 22.10. | BASTIDE: 2024-2025 annual results in line with targets // 2025-26 outlook: Revenue of over EUR 510 million and recurring operating margin around 9%, Leverage of less than 3x and decrease in financial expenses | 649 | Actusnews Wire | Caissargues, October 22, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has announced its 2024-2025 annual results at June 30, 2025. The 2024-2025 annual consolidated... ► Artikel lesen | |
| 24.09. | BASTIDE: Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group | 638 | Actusnews Wire | Caissargues, September 24, 2025
In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory... ► Artikel lesen | |
| 04.09. | BASTIDE: 2024-2025 revenue target met // 2024-2025 revenue from continuing operations: EUR 491 million, up 8% ( EUR 561 million, excluding impact of disposals) | 444 | Actusnews Wire | Caissargues, September 4, 2025
Groupe Bastide has published its annual revenue for 2024-2025. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no... ► Artikel lesen | |
| 23.07. | La Bastide: A Taste Of Provence, One Hour From New York City | 2 | Forbes | ||
| 30.06. | BASTIDE: Bastide Groupe Sells Baywater Healthcare To Sapio Group | 604 | Actusnews Wire | Crewe, United Kingdom & Monza, Italy - 30th June 2025
Bastide le Confort Medical SA (hereinafter "Groupe Bastide") today announced that it has agreed to the sale of its subsidiary Baywater Healthcare... ► Artikel lesen | |
| 09.06. | BASTIDE: Disposal of CICADUM and MEDSOFT | 508 | Actusnews Wire | Caissargues, June 9, 2025
Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned... ► Artikel lesen | |
| BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
| 05.06. | BASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium | 489 | Actusnews Wire | Caissargues, June 5, 2025
Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for... ► Artikel lesen | |
| 04.06. | BASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK | 433 | Actusnews Wire | Caissargues, June 4, 2025
After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region... ► Artikel lesen | |
| 15.05. | BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed | 452 | Actusnews Wire | Caissargues, May 15, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
| 19.03. | BASTIDE: 2024-2025 half-year results / Recurring operating margin at 9.1%, up 80 bps / Operating FCF positive at EUR 9.4 million / Improvement in financial leverage / upward revision of recurring operating margin target to 9.1% | 580 | Actusnews Wire | Caissargues, March 19, 2025 - Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025... ► Artikel lesen | |
| 13.02. | BASTIDE: Organic growth of 8.4% in first-half 2024 2025: Home healthcare services up 10.2% and Return to growth in the Homecare business / 2024-2025 targets confirmed | 453 | Actusnews Wire | Caissargues, February 13, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
| 08.01. | BASTIDE obtains an extended license to operate in Canada in the Respiratory Care segment / Sale of French stomatherapy subsidiary CICA PLUS | 400 | Actusnews Wire | Caissargues, January 8, 2025 - Groupe Bastide, one of Europe's leading players in home healthcare services, announces its newly extended license to operate in the field of respiratory care in British... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ANSELL | 20,200 | -0,98 % | ANSELL LIMITED: Change in substantial holding | ||
| AMBEA | 12,060 | +0,92 % | Ambea AB: Nytida acquires LSS and short-term care operations from Serigmo Invest | Nytida, part of the Ambea Group, has signed an agreement to acquire operations from Serigmo Invest Holding AB. The transaction includes the companies Serigmo Care KÅS AB and Villa Arelid AB, which provide... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,510 | +1,92 % | EQS-PVR: Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Siemens Healthineers AG
Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
01.12.2025 /... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,040 | +0,08 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,790 | +1,79 % | IPO Stock Of The Week: Health Care Leader BrightSpring Falls Back Into Buying Range | ||
| PROCEPT BIOROBOTICS | 35,860 | +1,21 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| FRESENIUS | 47,720 | -0,60 % | Fresenius-Aktie: Kaufen! | Die Aktie des Gesundheitskonzerns Fresenius hat sich in den zurückliegenden Wochen doch wieder spürbar von den Mehrjahreshochs Ende Oktober entfernt. An den mittel- bis langfristigen Aussichten für... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,550 | +0,77 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| GENEDX | 158,96 | -1,85 % | Cathie Wood's ARK sells Iridium, buys GeneDx and WeRide stock | ||
| PROGYNY | 24,020 | -0,54 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| BETA BIONICS | 29,380 | -2,07 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| NUTEX HEALTH | 160,95 | +2,65 % | Nutex Health extends share repurchase plan | ||
| GERRESHEIMER | 25,860 | -1,52 % | Gold, Drohnen und Spezialglas! Einfach mal 200 % aus dem Stand mit DroneShield, AJN Resources und Gerresheimer | Die Börse zeigt sich von der volatilen Seite. Während KI-, Rüstungs- und Tech-Aktien auch mal konsolidieren, schießen Gold und Silber durch die Decke. Die Branchenrotation ist zum Jahresende also voll... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 43,440 | +0,32 % | EQS-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Carl Zeiss Meditec AG
Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 9,310 | +1,92 % | Aveanna Healthcare stock price target raised to $13 by Raymond James |
Das Unternehmen BASTIDE LE CONFORT MEDICAL SA kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,39 % bei einem Aktienkurs von 25,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BASTIDE LE CONFORT MEDICAL SA finden Sie auf Wallstreet Online.